Inactive Instrument

All News Signal Genetics Inc Nasdaq

Equities

US8266401046

End-of-day quote Nasdaq Other stock markets
- ^USD	-

09/05	Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating	MT
09/05	B. Riley Downgrades Viridian Therapeutics to Neutral From Buy	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating	09/05	MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy	09/05	MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25	09/05	MT
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating	08/05	MT
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000	08/05	MT
Transcript : Viridian Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results	08/05	BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	06/05	AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05	BU
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	29/04	BU
Foghorn Therapeutics Names Kristian Humer CFO	16/04	MT
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04	BU
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29/03	PR
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	21/03	MT
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/03	BU
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05/03	BU
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating	28/02	MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Signal Genetics Inc Nasdaq

Equities

US8266401046

All News

Filters